Area of research
Oncology · Applied Microbiology and Biotechnology
Research interest
Research interests include Neutropenia and Cancer Infections, Antibiotic Use and Resistance, Antifungal resistance and susceptibility, and Bacterial Identification and Susceptibility Testing.
Antibody Titers of Vaccine-Preventable Pathogens at 1 Year Post CD19 CAR-T Cell Therapy
Comparing large language models for antibiotic prescribing in different clinical scenarios: which performs better?
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
Predictors of antibiotic prescription for upper respiratory infections in cancer patients.
Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.
Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation
Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy
Association Between Biliary Pathogens, Surgical Site Infection, and Pancreatic Fistula
Bacterial infections and antibiotic utilization varies by coronavirus disease 19 (COVID-19) severity in hospitalized cancer patients: Analysis from the first phase of the pandemic.
Impact of a Rapid Molecular Test for <i>Klebsiella pneumoniae</i> Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
SHEA statement on antibiotic stewardship in hospitals during public health emergencies
Development and evaluation of a structured guide to assess the preventability of hospital-onset bacteremia and fungemia
Development and evaluation of a structured guide to assess the preventability of hospital-onset bacteremia and fungemia.
Determinants of COVID-19 disease severity in patients with cancer
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Infectious Disease Complications in Patients with Cancer
Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience
Hospital epidemiologists’ and infection preventionists’ opinions regarding hospital-onset bacteremia and fungemia as a potential healthcare-associated infection metric
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States
Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies
The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis